StockNews.com Initiates Coverage on Oragenics (NYSE:OGEN)

StockNews.com began coverage on shares of Oragenics (NYSE:OGEN) in a report released on Sunday. The brokerage issued a sell rating on the stock.

Oragenics Trading Up 3.4 %

Shares of OGEN opened at $0.38 on Friday. Oragenics has a 52 week low of $0.25 and a 52 week high of $7.74. The firm has a market cap of $4.62 million, a price-to-earnings ratio of -0.05 and a beta of 0.43. The stock has a 50 day moving average of $0.33 and a 200-day moving average of $0.74.

About Oragenics

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.